摘要
目的:探讨度洛西汀和帕罗西汀对抑郁症伴有疼痛症状患者的临床疗效和安全性。方法:将抑郁症伴有疼痛症状的患者78例随机分为度洛西汀组(38例)和帕罗西汀组(40例),治疗8周,分别在治疗前和治疗后1、2、4、8周采用汉密尔顿抑郁量表(HAMD-24)、医学结局研究用疼痛量表(MOSPM)和治疗中出现的症状量表(TESS)评定疗效及安全性。结果:方差分析结果显示,在HAMD-24评分上,时间主效应有统计学意义(F=12.242,P=0.023);在MOSPM评分上,组别主效应有统计学意义(F=22.643,P=0.033),时间主效应有统计学意义(F=28.251,P=0.012),得分随治疗时间增加减少;组别和时间对HAMD-24及MOSPM评分的影响没有交互作用。结论:度洛西汀和帕罗西汀治疗抑郁症伴有疼痛患者均安全有效,度洛西汀对疼痛症状疗效更佳。
Objective： To compare the efficacy and safety of duloxetine and paroxetine in the treatment of major depressive disorder and associated painful physical symptoms. Method：Seventy-eight patients with ma- jor depressive disorder and associated painful physical symptoms were randomly assigned to receive duloxetine （n = 38 ） or paroxetine （n = 40 ） for 8 weeks in this controlled study. Efficacy and side effects were assessed with Hamilton depression rating scale （ HAMD-24 ）, medical outcomes study pain measurement （ MOSPM ） and treatment emergent symptom scale （ TESS ） respectively before and after treatment for 1,2,4,8 weeks. Results： Analysis of variance results indicated time main effect was statistically significant on HAMD-24 （ F = 12. 242, P = 0. 023 ） ; On MOSPM score group main effect was statistically significant （ F = 22. 643, P = 0. 033）and the time main effect was statistically significant （F = 28. 251, P = 0. 012）, score reduced with in- creasing treatment time ; There was no group x time interaction on HAMD-24 and MOSPM. Conclusion： Both duloxetine and paroxetine are effective and safe in the treatment of major depressive disorder and associated painful physical symptoms, duloxetine has better efficacy in treating painful physical symptoms than paroxetine.
出处
《临床精神医学杂志》
2013年第5期321-323,共3页
Journal of Clinical Psychiatry
关键词
度洛西汀
帕罗西汀
抑郁症
躯体疼痛
duloxetine
paroxetine
depression
painful physical symptoms
